🔍

GLAXO - Glaxosmi. Pharma

📊 NSE: GLAXO 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/13/2025 22:22

📢 Recent Corporate Announcements

GSK Pharma to Appoint Ronojit Biswas as Whole-time Director & CFO for 3-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 07 Mar 2026, 05:34 PM

GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot to seek shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed tenure is for three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the electronic voting process from March 9 to April 8, 2026, with final results expected by April 10, 2026. This leadership change is part of the company's planned management transition.

Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026.
E-voting period for shareholders is scheduled from March 9, 2026, to April 8, 2026.
The cut-off date for determining shareholder eligibility for voting was February 27, 2026.
The results of the postal ballot will be officially announced on or before April 10, 2026.

💡 Investors should take note of the leadership transition and monitor the official announcement of voting results on April 10, 2026. No immediate portfolio action is required as this is a standard management appointment.

GSK Pharma to Appoint Ronojit Biswas as WTD & CFO for 3-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 07 Mar 2026, 05:30 PM

GlaxoSmithKline Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed appointment is for a period of three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the decision via remote e-voting, which is scheduled to take place between March 9 and April 8, 2026. The results of the ballot will be declared on or before April 10, 2026.

Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026
Remote e-voting period scheduled from March 9, 2026, to April 8, 2026
Cut-off date for determining shareholder voting eligibility was February 27, 2026
Final results of the postal ballot to be announced by April 10, 2026

💡 This is a routine leadership appointment; investors should monitor the voting results for confirmation of the new CFO's tenure but no immediate action is required.

GSK Pharma Receives GST Demand of Rs 6.93 Crore for Alleged Non-Payment on Exports

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 07 Mar 2026, 10:42 AM

GlaxoSmithKline Pharmaceuticals Limited has received a tax demand order from the Maharashtra GST authorities totaling Rs. 6.93 crore. The demand, pertaining to the period April 2022 to March 2023, includes a tax component of Rs. 3.46 crore and an equivalent penalty of Rs. 3.46 crore. The issue relates to alleged non-payment of GST on the export of services. The company has stated that this development will not impact its financial operations and it will take appropriate legal actions.

Total demand of Rs. 6,92,76,478 raised by the Additional Commissioner, CGST & Central Excise, Mumbai Central
Demand includes a tax amount of Rs. 3,46,38,239 and a penalty of Rs. 3,46,38,239
The dispute concerns alleged GST liability on the export of services for the FY 2022-23 period
Company received the physical order on February 20, 2026, and plans to challenge the demand

💡 Investors should view this as a routine regulatory matter with minimal impact on the company's overall valuation. No immediate action is required as the company intends to contest the demand.

GSK Pharma Appoints Ronojit Biswas as CFO and Whole-Time Director

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 02 Mar 2026, 12:20 PM

GlaxoSmithKline Pharmaceuticals has appointed Mr. Ronojit Biswas as its new Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. He succeeds Mr. Juby Chandy, who will step down on March 11, 2026, to take on a senior regional role as APAC Finance lead within the GSK Group. Mr. Biswas is a company veteran with over 25 years of experience, having previously served as CFO for GSK's operations in Brazil and Vietnam. This transition represents a planned internal succession within the global GSK framework.

Mr. Ronojit Biswas appointed as CFO and Whole-Time Director for a 3-year term effective April 1, 2026.
Outgoing CFO Juby Chandy to transition to a new role leading APAC Finance within the GSK Group.
Mr. Biswas brings over 25 years of global experience with GSK, including leadership roles in Singapore, Brazil, and the UK.
The appointment was approved by the Board of Directors in a meeting held on March 2, 2026.

💡 Investors should monitor the transition but can take comfort in the appointee's extensive 25-year history with the parent group. No immediate impact on stock performance is expected from this routine internal leadership rotation.

GSK Pharma Appoints Ronojit Biswas as CFO; Juby Chandy to Transition to APAC Role

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 02 Mar 2026, 12:18 PM

GlaxoSmithKline Pharmaceuticals has announced the appointment of Mr. Ronojit Biswas as its new Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. He replaces the current CFO, Mr. Juby Chandy, who will step down on March 11, 2026, to take on a senior leadership role as the head of APAC Finance within the GSK Group. Mr. Biswas is a GSK veteran with over 25 years of experience, having previously served as CFO for GSK's operations in Brazil and Vietnam. This transition reflects a planned internal succession strategy within the multinational's global framework.

Mr. Ronojit Biswas appointed as CFO and Whole-Time Director for a 3-year term effective April 1, 2026.
Outgoing CFO Juby Chandy to transition to a regional role leading APAC Finance for GSK Group after March 11, 2026.
Incoming CFO Ronojit Biswas brings 25+ years of experience, including previous CFO roles in Brazil and Vietnam.
Mr. Biswas most recently served as Senior Finance Director – Global Product Strategy, based in Singapore.
The leadership change was approved during a board meeting held on March 2, 2026.

💡 This is a routine leadership transition within a multinational corporation; investors should monitor if the new CFO introduces any shifts in capital allocation or cost-management strategies.

DRI Conducts Search at GlaxoSmithKline Pharmaceuticals' Mumbai Office Under Customs Act

🔵 WATCH ⭐ 6/10

REGULATORY 📅 28 Feb 2026, 04:07 PM

The Directorate of Revenue Intelligence (DRI) initiated a search at the registered office of GlaxoSmithKline Pharmaceuticals in Mumbai on February 27, 2026. The action was carried out under Section 105 of the Customs Act, 1962, and concluded on February 28, 2026. The company has stated that it extended full cooperation to the authorities and that its business operations continue as usual. While the specific allegations are not yet disclosed, the company reports no immediate quantifiable impact on its financial or operational activities.

Search conducted by the Directorate of Revenue Intelligence (DRI) at the Mumbai headquarters.
Action initiated under Section 105 of the Customs Act, 1962, relating to import/export regulations.
Search operation spanned two days, starting February 27 and concluding on February 28, 2026.
Company confirms business operations remain unaffected with no immediate financial impact reported.

💡 Investors should remain cautious and monitor for subsequent disclosures regarding the findings of the DRI search. Any potential tax liabilities or penalties arising from this investigation could impact future earnings.

GSK Pharma Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone with 35.9% EBITDA Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Feb 2026, 05:04 PM

GlaxoSmithKline Pharmaceuticals reported a milestone quarter with revenue crossing ₹1,000 crores for the first time, achieving 10% consolidated growth. The company saw a significant EBITDA margin expansion of 520 basis points to 35.9%, driven by gross margin improvements and disciplined cost control. A major strategic shift is underway with the oncology foray, where the eligible patient pool for Jemperli expanded from 800 to 6,000 following regulatory approval for first-line endometrial cancer. The pediatric vaccine segment also maintained strong momentum with 11% growth during the quarter.

Quarterly revenue crossed the ₹1,000 crore mark for the first time with 8.1% standalone growth.
EBITDA margins improved by 520 basis points to 35.9% despite a ₹11.8 crore one-off labor cost impact.
Oncology target patient base increased to 6,000 following RUBY-1 trial approval for first-line endometrial cancer.
Pediatric vaccine portfolio grew by 11%, led by double-digit growth in Boostrix, Varilrix, and Havrix brands.
Strong liquidity position maintained with a cash balance of ₹2,426 crores as of Q3 FY2026.

💡 Investors should note the successful margin expansion and the strategic pivot toward high-value specialty oncology and adult vaccines. The significant increase in the addressable patient pool for new launches suggests a positive outlook for long-term revenue diversification.

GSK Pharmaceuticals Releases Recording of Analyst and Institutional Investor Meeting

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 04:23 PM

GlaxoSmithKline Pharmaceuticals Limited has officially shared the video recording link of its recent Analyst and Institutional Investor meeting held in February 2026. This disclosure is a mandatory compliance requirement under Regulation 30 of the SEBI (LODR) Regulations, 2015. The recording allows the broader investor community to access the same information and management commentary provided to institutional participants. Such interactions typically provide deeper insights into the company's strategic outlook and operational performance.

Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Recording of the Analyst/Institutional Investor meeting made available via the company's official website.
The filing was submitted to both BSE and NSE on February 11, 2026.
Provides transparency regarding management's discussions with institutional stakeholders.

💡 Investors should review the recording on the company's website to understand management's views on growth and the product pipeline. No immediate action is required as this is a routine regulatory filing.

GSK Pharma Releases Audio Recording of Analyst and Institutional Investor Meeting

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 07:27 PM

GlaxoSmithKline Pharmaceuticals Limited has officially released the audio recording of its recent Analyst and Institutional Investor meeting. The disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors can access the recording via the company's investor relations portal to gain insights into management's commentary. This is a routine regulatory filing following investor interactions to ensure transparency.

Audio recording of the Analyst/Institutional Investor meeting has been made public.
The filing complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Recording is hosted on the official GSK India website under the investors section.
The notification was submitted to both BSE Limited and the National Stock Exchange of India Limited.
The document was signed by Ajay Nadkarni, VP – Administration, Real Estate & Company Secretary.

💡 Investors should listen to the recording to understand management's perspective on business growth and operational performance. No immediate portfolio changes are recommended based on this routine administrative update.

GSK India Q3 FY26: Revenue up 8% to ₹1023 Cr, EBITDA Margins Expand to 35.9%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 03:47 PM

GlaxoSmithKline Pharmaceuticals Limited reported a steady 8.1% YoY revenue growth reaching ₹1023 crore for Q3 FY26, driven by General Medicines and a 11% growth in Pediatric Vaccines. The company achieved a significant EBITDA margin expansion of 520 bps to 35.9%, supported by gross margin improvements and an 11% rise in field productivity. PAT (before exceptional items) grew by 21.3% to ₹277 crore, reflecting strong operational leverage. The company is successfully scaling its specialty portfolio, particularly in Oncology and Adult Immunization (Shingrix), while maintaining a robust cash position of ₹2426 crore.

Revenue grew 8.1% YoY to ₹1023 crore, with Pediatric Vaccines growing at 11%
EBITDA surged 26.7% YoY to ₹368 crore, with margins expanding 520 bps to 35.9%
PAT (before exceptional items) increased 21.3% YoY to ₹277 crore
Shingrix (Adult Immunization) prescriptions grew 80% YoY to 50,000 in Q3
Maintained a healthy cash balance of ₹2426 crore and improved field productivity by 11%

💡 Investors should focus on the company's significant margin expansion and successful pivot towards high-growth specialty segments like Oncology and Adult Vaccines. The stock remains a strong play on operational efficiency and the premiumization of the Indian pharmaceutical market.

GSK India Q3 Revenue Crosses ₹1000 Cr, PAT at ₹277 Cr with 35.9% EBITDA Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 03:44 PM

GlaxoSmithKline Pharmaceuticals reported a strong Q3 FY26, with revenue from operations reaching INR 1,023 crores, representing an 8.1% growth. The company's profitability saw a significant boost as EBITDA margins expanded by 520 basis points to 35.9%, driven by improved gross margins and operating leverage. Key brands like Augmentin and Ceftum maintained market leadership, while the newly launched Oncology segment and Shingrix vaccine showed promising traction. Profit After Tax (PAT) for the quarter stood at INR 277 crores.

Revenue from operations crossed the INR 1,000 crore milestone, reaching INR 1,023 crores (+8.1% YoY)
EBITDA margins expanded significantly by 520 basis points to reach 35.9%
Profit After Tax (PAT) reported at INR 277 crores for the third quarter
General Medicines portfolio saw top five brands growing ahead of the market with an Evolution Index > 100
Oncology business, launched in August 2025, is gaining traction with therapies like Jemperli and Zejula

💡 Investors should note the significant margin expansion and the successful scale-up of the high-margin oncology and vaccine portfolios. The stock remains a strong defensive play in the MNC pharma space with improving growth levers.

GSK Pharma Q3 Consolidated Net Profit Rises 28.6% YoY to ₹295.6 Crore

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 03:22 PM

GlaxoSmithKline Pharmaceuticals reported a strong performance for Q3 FY26, with consolidated revenue growing 9.7% YoY to ₹1,041.3 crore. Net profit surged 28.6% YoY to ₹295.6 crore, aided by operational efficiencies and an exceptional gain of ₹18 crore from land sales. Despite a ₹11.8 crore impact from new labour code regulations on employee costs, the company maintained healthy margins. Profit before tax and exceptional items grew by 24% YoY, reflecting robust underlying business momentum.

Consolidated Revenue from Operations increased 9.7% YoY to ₹1,041.3 crore.
Consolidated Net Profit grew 28.6% YoY to ₹295.6 crore from ₹229.9 crore in the previous year.
Profit Before Tax (before exceptional items) rose 24% YoY to ₹382 crore.
Exceptional gain of ₹17.98 crore recorded from the sale of a non-operational land site.
Employee benefit expenses included a one-time impact of ₹11.82 crore due to new Labour Code valuations.

💡 Investors should view the strong bottom-line growth and margin expansion positively, even when accounting for the exceptional gain. The stock remains a solid defensive play in the pharmaceutical sector with steady revenue growth and operational discipline.

GlaxoSmithKline Pharmaceuticals Schedules Group Investor Meeting for February 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 10:26 AM

GlaxoSmithKline Pharmaceuticals Limited has announced a group meeting with analysts and institutional investors scheduled for February 9, 2026. The interaction will take place digitally to discuss information already available in the public domain. This notification is a standard compliance requirement under SEBI Listing Regulations. Investors should note that the schedule is subject to change based on exigencies of the company or participants.

Group investor and analyst meeting set for February 9, 2026
The meeting will be held through a digital platform
Company will only share information already in the public domain
Notification issued in compliance with SEBI Regulation 30

💡 No immediate action is required as this is a routine disclosure; however, investors may look for any subsequent presentation filings for updated management commentary.

GlaxoSmithKline Pharma Submits SEBI Compliance Certificate for Q3 FY2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 10:55 AM

GlaxoSmithKline Pharmaceuticals Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all share certificates received for dematerialization during the quarter ended December 31, 2025, were processed correctly. It verifies that the securities are listed on stock exchanges and that physical certificates were mutilated and cancelled within the mandatory 30-day period. This is a standard procedural filing to ensure the accuracy of the company's shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025
Confirmation provided by Registrar and Share Transfer Agent, KFin Technologies Limited
Verification that dematerialized securities are listed on the BSE and NSE
Physical share certificates were mutilated and cancelled as per SEBI guidelines
Register of members updated with depository names within the 30-day timeline

💡 This is a routine regulatory filing with no impact on the company's fundamentals. Investors should continue to monitor the company's upcoming quarterly financial results for performance insights.

GSK Pharma Receives GST Demand Order of ₹35.08 Lakh for FY 2021-22

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 01 Jan 2026, 02:31 PM

GlaxoSmithKline Pharmaceuticals Limited has received a tax demand order from the Maharashtra State GST authorities for the financial year 2021-22. The total demand amounts to ₹35.08 lakh, which includes tax, interest, and a penalty. The issue stems from GST credit mismatches between the company's returns and those reported by its suppliers. The company has stated that this order will have no significant impact on its financial operations and is currently evaluating its next steps.

Total demand of ₹35,07,895 issued by the Assistant Commissioner of State Tax, Mumbai
Demand breakdown includes ₹18,16,196 in tax, ₹15,10,080 in interest, and ₹1,81,619 in penalty
Order pertains to GST credit issues and mismatches for the FY 2021-22 period
Management confirms the order has no material impact on financial or operational activities

💡 No action is required as the demand amount is negligible compared to the company's scale of operations. This is a routine tax matter that does not affect the company's fundamental value.

View All GLAXO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Standalone revenue for Q2 FY26 was INR 974 Cr, a decline of 2.6% YoY. Pediatric vaccines grew by 13% YoY, while the adult vaccine (Shingrix) also saw double-digit growth. General Medicines business was flattish/declined due to a combined INR 70-75 Cr impact from supply issues and GST reforms.

Geographic Revenue Split

Not disclosed in available documents, though the company operates primarily in the Indian Pharmaceutical Market (IPM) with exports mentioned as an industry-wide factor.

Profitability Margins

Gross margins improved and are expected to be sustainable due to stable raw material prices. Net Profit After Tax (before exceptional items) for Q2 FY26 was INR 253 Cr, representing a 26.1% margin, which is a 150 bps improvement YoY.

EBITDA Margin

EBITDA margin reached 34.4% in Q2 FY26, a significant improvement of 250 basis points YoY, driven by cost savings, better product mix, and field cost productivity.

⚙️ Operational Drivers

Raw Materials

Specific chemical names not listed; however, raw materials are noted as having 'stable prices' with no current spikes, allowing for sustained gross margins.

Key Suppliers

The company relies on third-party Contract Manufacturing Organizations (CMOs). One specific CMO (unnamed) suffered a fire incident that caused a supply disruption.

Capacity Expansion

Not disclosed in available documents; however, the company is focusing on 'product transformation' by launching innovative assets like Jemperli and Zejula.

Raw Material Costs

Raw material costs are described as stable. The company focuses on expanding gross margins through a singular focus on cost consciousness and mitigating input cost fluctuations.

Manufacturing Efficiency

Field cost productivity has been maintained. The company is moving toward high-category growth innovative assets to improve overall profitability.

📈 Strategic Growth

Expected Growth Rate

10%+

Growth Strategy

Growth will be driven by the launch of the Oncology portfolio (Jemperli and Zejula), scaling of Specialty brands (Nucala, Trelegy), and double-digit growth in the Vaccine segment (Shingrix). The company aims to recover from Q2 headwinds to meet its double-digit ambition for the full year.

Products & Services

Pharmaceutical products including anti-infectives, pain medications, dermatologicals, oncology drugs (Jemperli, Zejula), and vaccines (Shingrix, pediatric vaccines).

Brand Portfolio

Calpol, Nucala, Trelegy, Shingrix, Jemperli, Zejula.

New Products/Services

Launched Oncology portfolio on August 15, 2025, featuring Jemperli (for endometrial cancer) and Zejula (for ovarian cancer). These are expected to contribute significantly in coming quarters.

Market Expansion

Focusing on Gyn-Oncology solutions for Indian patients and expanding the adult vaccination market through Shingrix.

Market Share & Ranking

Maintained a competitive market share of approximately 27.6% in relevant segments.

🌍 External Factors

Industry Trends

The industry is shifting toward specialty medicines and oncology. There is an increasing threat from generics and biosimilars due to patent expirations and India's strong generic export position.

Competitive Landscape

Faces competition from generic drug manufacturers and other multinational pharma companies in the acute and specialty segments.

Competitive Moat

Moat is built on strong brand equity (e.g., Calpol), a leadership position in vaccines, and a strategic shift toward high-margin, innovative specialty drugs that are harder to commoditize.

Macro Economic Sensitivity

The acute segment of the Indian Pharmaceutical Market (IPM) grew below 5% in Q2, indicating sensitivity to seasonal demand and overall market softness.

Consumer Behavior

Increased demand for adult vaccines (Shingrix) and specialized oncology treatments as patient awareness and diagnostic capabilities improve.

Geopolitical Risks

Global geopolitical tensions are cited as factors that disrupt supply chains and increase raw material cost volatility.

⚖️ Regulatory & Governance

Industry Regulations

Strict pricing regulations under the National List of Essential Medicines (NLEM) impact profit margins. Manufacturing must meet high GSK global quality standards.

Taxation Policy Impact

Impacted by GST reforms which had a transitionary revenue impact of INR 30-32 Cr in Q2 FY26.

Legal Contingencies

The company is evaluating a demand order (value not specified) and plans to take appropriate legal actions. No other specific court case values were disclosed.